Femasys Inc Stock News

-- Leading multi-site OB/GYN health practice to implement FemVue ® for fertility diagnostic evaluation and FemaSeed for first-line treatment across all four locations -- ATLANTA, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of ...

ATLANTA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today a partnership with CapexMD to expand patient access to its FemaSeed-led fertility portfolio thr...

-- For the first time, OB/GYNs within the UNC Health system will be able to offer women FemVue ® fertility evaluation and FemaSeed as a first-line treatment option -- ATLANTA, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care...

-- $30 million financing enables execution of U.S. commercial strategy for the FemaSeed ® fertility portfolio and advancement of the FemBloc ®  clinical and regulatory program toward U.S. approval -- ATLANTA, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designe...

-- New U.S. and international patents complement existing delivery system patents, extending global IP coverage for the FemBloc solution -- ATLANTA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce...

-- Potential proceeds would be received upon full cash exercise of warrants --  ATLANTA, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today that it has ente...

ATLANTA, June 24, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today that it received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) confirming the Company has regained compliance with Listing Rule 5550(a)(2), t...

-- New catheter complements FemVue® and supports streamlined in-office fertility evaluation -- -- New catheter complements FemVue® and supports streamlined in-office fertility evaluation --